Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Innovative Drug Development: Kalydeco Provides A Paradigm, FDA’s Spielberg Says

Executive Summary

The deputy commissioner detailed the steps involved in getting Vertex’s cystic fibrosis drug rapidly through the approval process and noted that FDA is working on innovative study designs and assessing how to better use diagnostics.

You may also be interested in...



Vertex’s Orkambi Efficacy Data May Make FDA More Cautious With Other ‘Breakthroughs’

Agency’s trial design recommendations made it difficult to assess lumacaftor’s contribution to the lumacaftor/ivacaftor fixed-dose combination’s efficacy in cystic fibrosis. The experience may color FDA’s future approach to combination product trial designs and how it advises other ‘breakthrough therapy’ sponsors on the evidence likely needed to support approval.

Vertex’s Latest Bid For Kalydeco Label Expansion Heads To FDA Panel

Supplemental NDA for use in adult cystic fibrosis patients with R117H mutation is based on a pre-specified subgroup analysis of 50 patients from a 69-patient pivotal trial that failed its primary efficacy endpoint.

FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes

Label expansion efforts for Vertex’s cystic fibrosis therapy will be claims taken through FDA’s new review pathway; the initial product could reach more patients more quickly and serve as a guide to how the agency will handle drugs earmarked for streamlined development and approval.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS054217

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel